Bright Minds Biosciences (TSE:DRUG)
:DRUG
DRUG Stock Chart & Stats
C$98.93
C$0.00(0.00%)
At close: 4:00 PM EST
C$98.93
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$33.01 - C$170.00
Previous CloseN/A
Volume70.00
Average Volume (3M)451.00
Market Cap
C$991.15M
Enterprise ValueC$678.90M
Total Cash (Recent Filing)C$89.05M
Total Debt (Recent Filing)C$104.90K
Price to Earnings (P/E)―
Beta24.74
Next Earnings
May 14, 2026EPS Estimate
-1.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.97
Shares Outstanding9,787,161
10 Day Avg. Volume620
30 Day Avg. Volume451
Financial Highlights & Ratios
PEG Ratio-0.27
Price to Book (P/B)7.07
Price to Sales (P/S)0.00
P/FCF Ratio-66.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$171.39Price Target Upside73.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-6.53
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial OpportunitySignificant unmet need in absence seizures and Prader-Willi Syndrome, combined with a convenient dosing profile and competitive efficacy signals, could drive meaningful clinical uptake and position the company for partnerships or acquisition interest.
Mechanism Of ActionBMB-101's G-protein–biased 5-HT2C agonism that avoids beta-arrestin recruitment offers a differentiated pharmacology that may reduce receptor desensitization and deliver more durable efficacy than older serotonergic anti-seizure drugs.
Registrational PathwayPhase 2 BREAKTHROUGH results substantially reduce clinical risk for BMB-101 and support plans to initiate registrational pivotal trials in absence seizures and developmental and epileptic encephalopathies, creating a clear path toward potential regulatory approval.
Bears Say
Competitive And Financing RiskDevelopment lags behind an established competitor in the same class, which could constrain market opportunity, while planned future equity raises could dilute existing shareholders and negatively affect valuation.
Long-term SafetyLong-term tolerability remains uncertain and additional safety data are required across both the epilepsy and genetic obesity programs to confirm sustained safety in broader patient populations.
Sample Size And Statistical RiskSmall patient numbers in the Phase 2 dataset limit confidence in the reproducibility and generalizability of the results, leaving material clinical risk despite encouraging responses.
Bright Minds Biosciences News
DRUG FAQ
What was Bright Minds Biosciences’s price range in the past 12 months?
Bright Minds Biosciences lowest stock price was C$33.01 and its highest was C$170.00 in the past 12 months.
What is Bright Minds Biosciences’s market cap?
Bright Minds Biosciences’s market cap is C$991.15M.
When is Bright Minds Biosciences’s upcoming earnings report date?
Bright Minds Biosciences’s upcoming earnings report date is May 14, 2026 which is in 50 days.
How were Bright Minds Biosciences’s earnings last quarter?
Bright Minds Biosciences released its earnings results on Feb 12, 2026. The company reported -C$0.97 earnings per share for the quarter, beating the consensus estimate of -C$1.186 by C$0.216.
Is Bright Minds Biosciences overvalued?
According to Wall Street analysts Bright Minds Biosciences’s price is currently Undervalued.
Does Bright Minds Biosciences pay dividends?
Bright Minds Biosciences does not currently pay dividends.
What is Bright Minds Biosciences’s EPS estimate?
Bright Minds Biosciences’s EPS estimate is -1.24.
How many shares outstanding does Bright Minds Biosciences have?
Bright Minds Biosciences has 9,787,161 shares outstanding.
What happened to Bright Minds Biosciences’s price movement after its last earnings report?
Bright Minds Biosciences reported an EPS of -C$0.97 in its last earnings report, beating expectations of -C$1.186. Following the earnings report the stock price went down -4.749%.
Which hedge fund is a major shareholder of Bright Minds Biosciences?
Currently, no hedge funds are holding shares in TSE:DRUG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bright Minds Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
C$171.39 (73.24% Upside)
C$171.39 (73.24% Upside)
Blogger Sentiment
Bullish
TSE:DRUG Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
―
20 days / 200 days
Momentum
145.60%
12-Months-Change
Fundamentals
Return on Equity
-30.79%
Trailing 12-Months
Asset Growth
736.23%
Trailing 12-Months
Company Description
Bright Minds Biosciences
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.
DRUG Stock 12 Month Forecast
Average Price Target
C$171.39
▲(73.24% Upside)
Technical Analysis
―
Entheon Biomedical
―
MYND Life Sciences
―
Universal Ibogaine Inc
―
Mindbio Therapeutics Corp.
―
Options Prices
Currently, No data available
---